Cat. No. | Product Name | Field of Application | Chemical Structure |
---|---|---|---|
DC67529 | DM4-SMCC |
DM4-SMCC is an antibody-drug conjugate (ADC) payload that combines the potent antitubulin agent DM4 with a non-cleavable SMCC linker. This conjugate is designed to deliver cytotoxic effects specifically to tumor cells, leveraging DM4's ability to disrupt microtubule dynamics. The stable SMCC linker ensures controlled drug release, enhancing the ADC's antitumor activity while minimizing off-target toxicity.
More description
|
![]() |
DC66368 | sulfo-SPDB-DM4 Featured |
sulfo-SPDB-DM4 is a agent-linker conjugate for ADC by using the maytansinebased payload (DM4, an antitubulin agent) via the sulfo-SPDB linker.
More description
|
![]() |
DC8539 | DM1-SMCC Featured |
DM1-SMCC is DM1 with a reactive linker SMCC, which can react with antibody to make antibody drug conjugate.
More description
|
![]() |
DC31389 | SGD-1269(MCMMAF) Featured |
Mafodotin, also known as mc-MMAF and SGD-1269 or Maleimidocaproyl monomethylauristatin F, is a MMAF derivative having a Maleimidocaproyl linker (MC linker), which is ready to conjugate to antibody or other proteins or biopolymers. Mafodotin is a useful a
More description
|
![]() |
DC50025 | Deruxtecan Featured |
Deruxtecan, a topoisomerase I inhibitor, is an exatecan derivative (DX-8951 derivative) with a cleavable pepetide linker and a maleimide group. The maleimide group in Deruxtecan can react with antibody to form antibody-drug conguates (ADC) such as Trastuzumab deruxtecan (DS-8201a), which is a HER2-targeting antibody–drug conjugate.
More description
|
![]() |
DC39818 | CL2-SN-38(DCA) Featured |
CL2-SN-38 is a cleavable linker-based antibody-drug conjugate (ADC) containing the topoisomerase I inhibitor SN-38 (Item No. 15632) and a maleimidocaproyl linker.1 CL2-SN-38 has been linked to tumor-selective human monoclonal antibodies, such as anti-CEACAM5 (hMN-14) to target SN-38 to tumor sites and improve its solubility. CL2-SN-38 linked to hMN-14 binds (Kd = 1.4 nM) and is cytotoxic to LoVo human colon adenocarcinoma cells (IC50 = 5.3 nM). CL2-SN-38 linked to hMN-14 increases survival in a colon carcinoma mouse model of lung metastasis.
More description
|
![]() |
DC7556 | VcMMAE Featured |
VcMMAE is an antibody-drug conjugate (ADC) with potent antitumor activity by using the anti-mitotic agent, monomethyl auristatin E (MMAE), linked via the lysosomally cleavable dipeptide, valine-citrulline (vc).
More description
|
![]() |
DC11013 | Tesirine |
Tesirine ( SG3249) is a cathepsin B-cleavable valine-alanine pyrrolobenzodiazepine (PBD) dimer as antibody-drug conjugate (ADC) payload.
More description
|
![]() |
DC42455 | Acetylene-linker-Val-Cit-PABC-MMAE Featured |
Acetylene-linker-Val-Cit-PABC-MMAE (LCB14-0602) consists the ADCs linker (Acetylene-linker-Val-Cit-PABC) and potent tubulin (MMAE). Acetylene-linker-Val-Cit-PABC-MMAE (LCB14-0602) is a drug-linker conjugate for ADC.
More description
|
![]() |
DC71950 | Ac-Lys-Val-Cit-PABC-MMAE Featured |
Ac-Lys-Val-Cit-PABC-MMAE is a drug-linker conjugate for ADC. Ac-Lys-Val-Cit-PABC-MMAE contains the ADC linker (peptide Ac-Lys-Val-Cit-PABC) and a potent tubulin polymerization inhibitor MMAE.
More description
|
![]() |
DC47680 | PSMA-Val-Cit-PAB-MMAE Featured |
PSMA-Val-Cit-PAB-MMAE is a novel small-molecule PSMA-targeted conjugate based on the monomethyl auristatin E for the chemotherapy of prostate cancer.
More description
|
![]() |
DC80073 | Azido-PEG4-EV-Cit-PAB-MMAE Featured |
Azido-PEG4-EV-Cit-PAB-MMAE is a precursor of antibody drug conjugate.
More description
|
![]() |
DC74470 | SuO-Val-Cit-PAB-MMAE Featured |
A drug-linker conjugate for antibody-drug conjugate by using the anti-mitotic agent, monomethyl auristatin E (MMAE), linked via the cleavable peptide SuO-Val-Cit-PAB..
More description
|
![]() |
DC71115 | SN38 NHS ester Featured |
SN38 NHS ester is the NHS ester derivative of SN38. SN-38 is an active metabolite of the Topoisomerase I inhibitor Irinotecan. SN-38 inhibits DNA and RNA synthesis. SN38 NHS ester can be used for the synthesis of antibody-drug conjugates (ADCs).
More description
|
![]() |
DC40590 | DBCO-PEG4-MMAF Featured |
DBCO-PEG4-MMAF is a drug-linker conjugate for ADC with potent antitumor activity by using the tubulin polymerization inhibitor, MMAF, linked via the cleavable linker DBCO-PEG4.
More description
|
![]() |
DC46408 | Gly3-VC-PAB-MMAE Featured |
Gly3-VC-PAB-MMAE consists a cleavable ADC linker (Gly3-VC-PAB) and a potent tubulin inhibitor (MMAE). Gly3-VC-PAB-MMAE can be used in the synthesis of antibody-drug conjugates (ADCs).
More description
|
![]() |
DC46199 | DBCO-PEG4-Ahx-DM1 Featured |
DBCO-PEG4-Ahx-DM1 is a drug-linker conjugate composed of a potent microtubulin inhibitor DM1 and a linker DBCO-PEG4-Ahx to make antibody drug conjugate (ADC). Mertansine (DM1) is a microtubulin inhibitor and is an antibody-conjugatable maytansinoid that is developed to overcome systemic toxicity associated with maytansine and to enhance tumor-specific delivery.
More description
|
|
DC57082 | MC-MMAE Featured |
Mc-MMAE is a protective group (maleimidocaproyl)-conjugated monomethyl auristatin E (MMAE), which is a potent tubulin inhibitor. Mc-MMAE is a drug-linker conjugate for ADC.
More description
|
![]() |
DC74472 | EN106 derivative 2 |
EN106 derivative 2 is a EN106 derivative used for PROTAC design, EN106 is a covalent ligand and recruiter for FEM1B E3 ligase for targeted protein degradation.
More description
|
![]() |
DC74471 | EN106 derivative 1 |
EN106 derivative 1 is a EN106 derivative used for PROTAC design, EN106 is a covalent ligand and recruiter for FEM1B E3 ligase for targeted protein degradation.
More description
|
![]() |
DC74469 | ZD06519 |
ZD06519 is a novel camptothecin payload for antibody drug conjugates (ADCs) with highp ayload potency (~1 nM).
More description
|
![]() |
DC10159 | N3-PEG3-vc-PAB-MMAE Featured |
N3-PEG3-vc-PAB-MMAE is a drug-linker conjugate for ADC with potent antitumor activity by using the anti-mitotic agent, monomethyl auristatin E (MMAE), linked via the peptide N3-PEG3-vc-PAB.
More description
|
![]() |
DC71665 | Val-Cit-PAB-MMAF Featured |
Val-Cit-PAB-MMAF is a drug-linker conjugate for ADC. Val-Cit-PAB-MMAF contains the ADCs linker (peptide Val-Cit-PAB) and a potent tubulin polymerization inhibitor MMAF.
More description
|
![]() |
DC72119 | Deruxtecan analog 2 |
Deruxtecan analog 2 (example 9 P3) is a Deruxtecan analog. Deruxtecan analog 2 is a drug-linker conjugate composed of Camptothecin and a linker. Camptothecin (CPT) is a Topo I inhibitor with antineoplastic activity against colorectal, breast, lung and ovarian cancers. Deruxtecan analog 2 can be used for the preparation anti-FGFR2 ADC.
More description
|
![]() |
DC10120 | MC-Val-Cit-PAB Featured |
MC-Val-Cit-PAB, also known as MC-Val-Cit-PAB-OH, is a cathepsin cleavable ADC peptide linker. MC-Val-Cit-PAB is useful for making ADC conjugate (antibody-drug conjugate). FDA approved drugs such as brentuximab vedotin used this linker.
More description
|
![]() |
DC72532 | Fmoc-VAP-MMAE |
Fmoc-VAP-MMAE is a drug-linker conjugates for ADC. Fmoc-VAP-MMAE consists of an ADC linker and a tubulin inhibitor MMAE, with a protective Fmoc group.
More description
|
![]() |
DC72533 | ATAC21 |
ATAC21, a linker-immune-stimulatory compound that can be formed by conjugating a noncleavable maleimide-PEG4 linker containing a succinimide group with an immune- stimulatory compound. ATAC21 can be combined with SBT-040 (anti-CD40 antibody) to form a conjugate.
More description
|
![]() |
DC72257 | TAM558 |
TAM558 is a payload molecule used for the synthesis of OMTX705. OMTX705 is a humanized anti-fibroblast-activating protein (FAP) antibody conjugated to the cytolysin TAM470, with antitumor activity.
More description
|
![]() |
DC46214 | Sulfo-SPDB-DGN462 |
Sulfo-SPDB-DGN462 is a drug-linker conjugate for ADC. Sulfo-SPDB-DGN462 consists a toxin DGN462 conjugated to the cleavable Sulfo-SPDB linker. DGN462, a potent DNA-alkylating agent, shows anti-tumor activity, such as acute myeloid leukemia (AML).
More description
|
![]() |
DC46259 | MRTX849 ethoxypropanoic acid |
MRTX849 ethoxypropanoic acid incorporates a ligand for KRAS G12C, and a PROTAC linker. MRTX849 ethoxypropanoic acid can be used in the synthesis of PROTAC LC-2. LC-2 is a potent and first-in-class PROTAC capable of degrading endogenous KRAS G12C (DC50s between 0.25 and 0.76 μM).
More description
|
![]() |